Concomitant inhibition of primary equine bronchial fibroblast proliferation and differentiation by selective β2-adrenoceptor agonists and dexamethasone.

The research article investigates how bronchial asthma, chronic obstructive pulmonary disease (COPD), and equine recurrent airway obstruction (RAO) can be affected by β2-adrenoceptor agonists and glucocorticoids that inhibit cell proliferation. Using primary equine bronchial fibroblasts (EBF) as the experimental model, the research observes the impact of these drugs on proliferation, differentiation, and collagen synthesis of cells.

Objective and Methodology:

• The study aims to understand the role of altered airway cell proliferation in underlying conditions like human bronchial asthma, COPD, and equine RAO, and how β2-adrenoceptor agonists and glucocorticoids regulate this proliferation.
• The researchers used equine bronchial fibroblasts (EBF) to investigate the effect of long-acting (clenbuterol) and short-acting (salbutamol and isoproterenol) β2-agonists and dexamethasone on cell proliferation, differentiation, and collagen synthesis.

Findings:

• A high density of β2-adrenoceptor subtype was expressed in EBF.
• The β2-agonists inhibited EBF proliferation in a concentration-dependent manner with clenbuterol being more potent than salbutamol and isoproterenol.
• Dexamethasone alone had a lesser inhibitory effect on EBF proliferation, but its effect was significantly amplified when combined with β2-agonists.
• Transforming growth factor-β1 (TGF-β1) induced transformation of fibroblasts into myofibroblasts was inhibited by clenbuterol and dexamethasone. The drug combination resulted in a high inhibition rate.
• Collagen synthesis in EBF was more hindered by dexamethasone than by β-agonists.

Conclusion:

• The study suggests that the expression of β2-adrenoceptor subtype in EBF and the anti-proliferative effect of clenbuterol indicates that β2-adrenoceptors play an inhibitory and anti-fibrotic role in EBF.
• The inhibitory effects of β2-agonists in EBF were synergistically enhanced by dexamethasone, suggesting a possible additive therapeutic effect of glucocorticoids to counteract airway remodeling and morbidity associated with asthma and RAO.